23.03.2017
Evotec AG DE0005664809
DGAP-News: EVOTEC TO ATTEND THREE UPCOMING INVESTOR CONFERENCES
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC TO ATTEND THREE UPCOMING INVESTOR CONFERENCES
23.03.2017 / 11:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 23 March 2017:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that its management will be presenting at the European
Capital Markets Conference in Munich, Germany, and will be attending the
Bankhaus Lampe Deutschlandkonferenz in Baden-Baden, Germany, and the 10th
Kempen & Co Life Sciences Conference in Amsterdam, The Netherlands.
Bankhaus Lampe Deutschlandkonferenz, Baden-Baden, Germany
* Date: Wednesday, 29 March 2017
* Venue: Baden-Baden, Germany
* Attendee: Enno Spillner, Chief Financial Officer of Evotec AG
European Capital Markets Conference, Munich, Germany
* Date: Wednesday, 12 April 2017
* Venue: Munich, Germany
* Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG
10th Kempen & Co Life Sciences Conference, Amsterdam, The Netherlands
* Date: Wednesday, 19 April 2017
* Venue: Amsterdam, The Netherlands
* Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG
About Evotec AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the- art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases.
On this basis, Evotec has built a broad and deep pipeline of more than 70
partnered product opportunities at clinical, pre-clinical and discovery
stages (EVT Innovate). Evotec has established multiple long-term discovery
alliances with partners including Bayer, CHDI, Sanofi or UCB and development
partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's
disease, with Sanofi in the field of diabetes, with Pfizer in the field of
tissue fibrosis and with Celgene in the field of neurodegenerative diseases.
For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
23.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
557467 23.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT